Jul. 23 at 12:04 PM
🔁 8:00am EST PM Update
$CLSD – Cleared FDA approval for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use. A key milestone for Clearside, with commercialization now in sight.
$DALN – Received an unsolicited non-binding acquisition proposal. Confirmation came early this morning, pushing volume and speculative interest into premarket.
$HIND – Progressing toward merger with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys. Also announced strategic cost reductions, cutting
$750K+ in payroll expenses. Shareholder meeting set for July 24.
$LTRN – Reported a complete response in a heavily pre-treated advanced cancer patient from its LP-184 Phase 1A trial. Promising signal for Lantern’s clinical pipeline.
$WLGS – No new headlines, but still moving aggressively, now up 87% from our alert in yesterday’s AH session. Watching for further squeeze setup.
⚡ Market Tone: Catalysts gaining traction—biotech approvals, merger updates, acquisition buzz.
